Last reviewed · How we verify
NCT03155984
Optimizing HBV Management During Anti-CD20 Antibodies
trial testing Anti-CD20 antibody in Liver Dysfunction in 83 participants. Completed in 1 December 2017.
1 June 2017
Quick facts
| Lead sponsor | The University of Hong Kong |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 83 |
| Start date | 1 October 2013 |
| Primary completion | 1 June 2017 |
| Estimated completion | 1 December 2017 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Anti-CD20 antibody — full drug profile →
Conditions studied
- Liver Dysfunction — all drugs for Liver Dysfunction →
- Immune Suppression — all drugs for Immune Suppression →
- Hepatitis B — all drugs for Hepatitis B →
Sponsor
The University of Hong Kong
Who can join
18 and older, any sex, with Liver Dysfunction or Immune Suppression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hepatitis B virus (HBV) reactivation is common during anti-CD20 containing chemotherapy, even in HBsAg-negative patients with only prior HBV exposure. The optimal timing of commencing antiviral therapy and the interval of clinical monitoring is uncertain. 25% of the Hong Kong population has prior HBV exposure. The investigators plan monitor this cohort of patients and determine (1) the optimal time point for starting antiviral therapy based on the progression of HBV reactivation, and (2) the optimal interval of clinical monitoring.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03155984
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-CD20 antibody
Trials testing the same drug.
- NCT06586177 — Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies · recruiting
Other recruiting trials for Liver Dysfunction
Currently open trials in the same condition.
- NCT06173947 — SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury · recruiting
- NCT06532214 — Clinical Retrospective Study Analysis of Postoperative Complications Following Hepatectomy · recruiting
- NCT05793203 — Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transp · recruiting
- NCT03519074 — Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction · Phase 2 · active not recruiting
Other The University of Hong Kong trials
Trials by the same sponsor.
- NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
- NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
- NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03155984 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
- Last refreshed: 4 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03155984.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing